Monitoring10 min readUpdated 2025-04-03

    GLP-1 Is It Working? Signs Your Medication Is Effective

    How to tell if your GLP-1 medication is working. Identify early signs of effectiveness, understand realistic timelines, and know when to talk to your provider about semaglutide or tirzepatide.

    Early Signs Your GLP-1 Is Working

    Not all signs of effectiveness show up on the scale. Here are the earliest indicators that your semaglutide or tirzepatide is doing its job.

    Reduced Food Noise (Week 1-2)

    The constant thinking about food quiets down. You stop planning your next meal while eating the current one. This is often the very first sign patients notice.

    Feeling Full Faster (Week 1-3)

    Meals that you used to finish easily now leave you satisfied halfway through. Your portions naturally decrease without conscious effort.

    Reduced Cravings (Week 2-4)

    Sugar cravings, late-night snacking urges, and emotional eating triggers diminish. Many patients report being able to walk past treats without a second thought.

    Scale Movement (Week 2-6)

    Initial weight loss begins, often 2-5 pounds in the first month. This accelerates as doses increase during titration.

    Effectiveness Timeline

    Month 1

    Appetite changes, 2-5 lbs lost, adjusting to medication

    Month 3

    5-15 lbs lost, clothes fitting differently, energy improving

    Month 6

    10-25+ lbs lost, visible transformation, lab markers improving

    Month 12

    15-20% body weight lost on average, metabolic health significantly improved

    Signs It May Not Be Working Optimally

    No appetite change after 4+ weeks at current dose

    You may need a dose increase. The starting dose is often sub-therapeutic for appetite suppression.

    Less than 5% weight loss after 3 months at maintenance dose

    Consider whether dietary habits, medication interactions, or underlying conditions may be factors. Discuss with your provider.

    Initial response followed by complete stall

    Plateaus of 2-3 weeks are normal. A stall of 6+ weeks at a stable dose may warrant evaluation and potential dose or medication adjustment.

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Individual responses to GLP-1 medications vary. Always consult your healthcare provider about treatment effectiveness.

    Frequently Asked Questions

    How long does it take for GLP-1 medication to start working?

    Most patients notice appetite reduction within the first 1-2 weeks. Weight loss typically begins within 2-4 weeks but may be modest at starting doses. Full effectiveness is usually reached at the maintenance dose, around months 3-4.

    What are the first signs that semaglutide or tirzepatide is working?

    Reduced appetite and food noise are usually the first signs, often within days. Feeling full faster during meals, less interest in snacking, and reduced cravings follow. Weight loss on the scale typically comes after these appetite changes.

    What if I don't lose weight in the first month?

    Starting doses are intentionally low to minimize side effects and are not expected to produce maximum weight loss. Many patients don't see significant scale movement until reaching higher doses. Focus on appetite changes as early markers of effectiveness.

    When should I worry that my GLP-1 isn't working?

    If you've been on a maintenance dose for 3+ months with no weight loss, minimal appetite changes, and no improvement in metabolic markers, discuss alternatives with your provider. You may need a dose increase or a switch to a different medication.

    Start Your GLP-1 Treatment Today

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: March 12, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Know the critical warning signs while on GLP-1 medications. Learn when to call your doctor, visit the ER, or stop semaglutide or tirzepatide. Your safety guide for GLP-1 treatment.

    Create a comprehensive monthly GLP-1 progress report. Compile weight trends, side effects, measurements, and lab results to optimize your semaglutide or tirzepatide treatment.

    Learn the best techniques for taking GLP-1 weight loss progress photos. Consistent lighting, angles, and timing help you accurately track semaglutide and tirzepatide results.

    Use this weekly GLP-1 check-in template to track your semaglutide or tirzepatide progress. Monitor weight, side effects, appetite, energy, and treatment effectiveness.

    Start your GLP-1 journey — from $99/mo

    Get Started